NIVOLUMAB COMBINED WITH BRENTUXIMAB VEDOTIN FOR RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA: EFFICACY AND SAFETY RESULTS FROM THE PHASE 2 CHECKMATE 436 STUDY
EHA Learning Center, Pier Luigi Zinzani, 267355
SAFETY AND EFFICACY OF COMBINATION OF SELINEXOR, DARATUMUMAB, AND DEXAMETHASONE (SDD) IN PATIENTS WITH MULTIPLE MYELOMA (MM) PREVIOUSLY EXPOSED TO PROTEASOME INHIBITORS AND IMMUNOMODULATORY DRUGS
EHA Learning Center, Cristina J. Gasparetto, 267360
MARS: MUTATION-ADJUSTED RISK SCORE FOR ADVANCED SYSTEMIC MASTOCYTOSIS
EHA Learning Center, Mohamad Jawhar, 267365
MEASURABLE RESIDUAL DISEASE MONITORING IN ACUTE MYELOID LEUKEMIA (AML) WITH T(8;21)(Q22;Q22.1); RUNX1-RUNX1T1: RESULTS OF THE AML STUDY GROUP (AMLSG)
EHA Learning Center, Frank G. Rücker, 267370
CLINICAL EFFICACY OF A NOVEL VALIDATED PROGNOSTIC INDEX FOR TRIAL DESIGN IN ADULT ACUTE LYMPHOBLASTIC LEUKAEMIA.
EHA Learning Center, Anthony Moorman, 267375
INCOMPLETE COUNT RECOVERY IN PATIENTS WITH COMPLETE REMISSION PRIOR TO ALLOGENEIC HCT FOR AML IS ASSOCIATED WITH A HIGH NON-RELAPSE MORTALITY WITHOUT AN INCREASED RELAPSE RISK
EHA Learning Center, Andrew INNES, 267380
UNEXPECTED DIFFERENCES IN CARDIAC IRON METABOLISM AND SURVIVAL IN HAMP-KO AND FPN(C326S) MICE
EHA Learning Center, Sandro Altamura, 267385
FRACTIONATED DOSING OF ARI-0001 CELLS (A3B1:CD8:4-1BB:CD3Z CAR19) AND EARLY TOCILIZUMAB ADMINISTRATION MAY REDUCE THE INCIDENCE OF SEVERE CYTOKINE RELEASE SYNDROME IN PATIENTS WITH CD19+ MALIGNANCIES
EHA Learning Center, Valentín Ortiz-Maldonado, 267390
INFECTIOUS COMPLICATIONS IN PATIENTS RECEIVING ANTI-CD 19 CHIMERIC ANTIGEN RECEPTORS T-CELLS (CAR T) FOR DIFFUSE LARGE B CELL LYMPHOMA (DLBCL). A MONOCENTRIC PRELIMINARY EXPERIENCE.
EHA Learning Center, Roberta Di Blasi, 267395
THE COMBINATION OF LOW ADAMTS-13 ACTIVITY AND HIGH ANTI-ADAMTS13 ANTIBODIES AT REMISSION HIGHLY PREDICTS DISEASE RELAPSE IN PATIENTS WITH ACQUIRED TTP: A MULTI-INSTITUTIONAL STUDY
EHA Learning Center, Francesca Schieppati, 267400
REAL-WORLD RESULTS ON CD19 CAR T-CELL FOR 60 FRENCH PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA INCLUDED IN A TEMPORARY AUTHORIZATION FOR USE (ATU) PROGRAM
EHA Learning Center, Catherine Thieblemont, 267354
HORIZON (OP-106): UPDATED EFFICACY AND SAFETY OF MELFLUFEN IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO DARATUMUMAB (DARA) AND/OR POMALIDOMIDE (POM)
EHA Learning Center, Paul G. Richardson, 267359
MASKED POLYCYTHEMIA VERA: ANALYSIS OF A SINGLE CENTER SERIES OF 2480 RED CELL MASSES.
EHA Learning Center, Juliette SORET-DULPHY, 267364
SAFETY, EFFICACY, AND BIOMARKERS OF RESPONSE TO AZACITIDINE (AZA) WITH NIVOLUMAB (NIVO) AND IPILIMUMAB (IPI), AND AZA WITH NIVO IN R/R ACUTE MYELOID LEUKEMIA: A NON-RANDOMIZED, PHASE 2 STUDY.
EHA Learning Center, Naval Daver, 267369
NELARABINE AS SALVAGE THERAPY AND BRIDGE TO ALLOGENEIC STEM CELLS TRANSPLANTATION IN 118 ADULT PATIENTS WITH RELAPSED/REFRACTORY T-ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA. A CAMPUS-ALL, PHASE 4, STUDY.
EHA Learning Center, Anna CANDONI, 267374
REDUCTION OF GRAFT-VERSUS-HOST DISEASE USING DUAL LYMPHOCYTE SUPPRESSION WITH ANTI-THYMOCYTE GLOBULIN AND LOW-DOSE POST-TRANSPLANT CYCLOPHOSPHAMIDE IN HAPLOIDENTICAL PATIENTS AT HIGH GVHD RISK
EHA Learning Center, Yu Wang, 267379
A PHASE IIA STUDY TO EVALUATE THE SAFETY, PK AND PD OF REPEATED ADMINISTRATIONS OF THE HEPCIDIN ANTAGONIST PRS-080 IN ANEMIC CHRONIC KIDNEY DISEASE PATIENTS UNDERGOING HEMODIALYSIS
EHA Learning Center, Lutz Renders, 267384
ACADEMIC, PHASE1 TRIAL ON T CELLS EXPRESSING BOTH CD19 CHIMERIC ANTIGEN RECEPTOR AND INDUCIBLE CASPASE 9 SAFETY SWITCH FOR TREATMENT OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKAEMIA AND NON-HODGKIN LYMPHOMA
EHA Learning Center, Francesca del bufalo, 267389
POLYMORPHISMS IN CYTOKINES, CHEMOKINES AND THEIR RECEPTORS GENES CONTRIBUTED TO CYTOMEGALOVIRUS REACTIVATION AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
EHA Learning Center, Miren Vallejo, 267394
NEUTROPHIL TO LYMPHOCYTE RATIO, PLATELET TO LYMPHOCYTE RATIO, AND RISK OF THROMBOEMBOLISM IN PATIENTS WITH LYMPHOMA RECEIVING CHEMOTHERAPY
EHA Learning Center, Vladimir Otasevic, 267399
RITUXIMAB MAINTENANCE FOR PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IN FIRST COMPLETE REMISSION: RESULTS FROM A RANDOMIZED HOVON-NORDIC LYMPHOMA GROUP PHASE III STUDY
EHA Learning Center, Pieternella LUGTENBURG, 267353
EFFECTIVENESS OF DENOSUMAB COMPARED TO ZOLEDRONIC ACID IN BONE DISEASE TREATMENT OF MULTIPLE MYELOMA (MM): A META-ANALYSIS
EHA Learning Center, James Abraham Malala, 267358
THREE-YEAR ANALYSIS OF THE DALIAH TRIAL - A RANDOMIZED CONTROLLED PHASE III CLINICAL TRIAL COMPARING RECOMBINANT INTERFERON ALPHA-2 VS. HYDROXYUREA IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS
EHA Learning Center, Trine Alma Knudsen, 267363
CHROMOSOMAL ABNORMALITIES DETERMINE OUTCOME IN NPM1MUT/FLT3-ITDNEG/LOW ACUTE MYELOID LEUKEMIA
EHA Learning Center, Linus Angenendt, 267368
BLINATUMOMAB FOR MINIMAL RESIDUAL DISEASE (MRD) IN ADULTS WITH B­CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BCP­ALL): MEDIAN OVERALL SURVIVAL (OS) NOT REACHED AT 5 YEARS FOR COMPLETE MRD RESPONDERS
EHA Learning Center, Nicola Goekbuget, 267373
A DAY 100 LAB-SCORE PREDICTS EXTENSIVE CGVHD, OVERALL SURVIVAL AND TRANSPLANT-RELATED MORTALITY AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: FINAL ANALYSIS
EHA Learning Center, Andrea Bacigalupo, 267378
ERFE-A260S ACCOUNTS FOR HEPATIC IRON METABOLISM IMPAIRMENT BY ACTING ON THE BMP-SMAD PATHWAY
EHA Learning Center, Roberta Russo, 267383
A PHASE I FIRST-IN-HUMAN CLINICAL TRIAL OF CD19-TARGETED 19-28Z/4-1BBL “ARMORED” CAR T CELLS IN PATIENTS WITH RELAPSED OR REFRACTORY NHL AND CLL INCLUDING RICHTER TRANSFORMATION
EHA Learning Center, M. Lia Palomba, 267388
SAFETY AND EFFICACY OF LIVE ATTENUATED VARICELLA VACCINE FOR PREVENTING VARICELLA ZOSTER VIRUS DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A PROSPECTIVE SINGLE-CENTER STUDY
EHA Learning Center, Koji Kawamura, 267393
ASSOCIATION OF SYSTEMIC CYTOKINE LEVELS WITH RISK OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH GLIOMA
EHA Learning Center, Pegah Mir Seyed Nazari, 267398
BASELINE TOTAL METABOLIC TUMOR VOLUME IS HIGHLY PROGNOSTIC FOR REFRACTORINESS TO IMMUNOCHEMOTHERAPY IN DLBCL: AN ANALYSIS OF THE PHASE 3 GOYA TRIAL
EHA Learning Center, Marek Trneny, 267352
FIRST CLINICAL (PHASE 1B/2A) STUDY OF IBERDOMIDE (CC-220; IBER), A CELMOD, IN COMBINATION WITH DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
EHA Learning Center, Sagar LONIAL, 267357
RUXOLITINIB PLUS POMALIDOMIDE IN MYELOFIBROSIS WITH ANEMIA: RESULTS FROM THE MPNSG-0212 COMBINATION TRIAL (NCT01644110)
EHA Learning Center, Frank Stegelmann, 267362
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION CAN ABROGATE INCREASING RISK OF RELAPSE FROM PERSISTENT MUTATIONS MEASURED BY TARGETED SEQUENCING AT REMISSION IN NORMAL KARYOTYPE ACUTE MYELOID LEUKEMIA
EHA Learning Center, Taehyung Kim, 267367
TISAGENLECLEUCEL APPEARS EFFECTIVE AND SAFE IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA WITH HIGH-RISK CYTOGENETIC ABNORMALITIES
EHA Learning Center, Stephan A. Grupp, 267372
INTESTINAL MICROBIOTA CAN PREDICT AGVHD FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
EHA Learning Center, Lijie HAN, 267377
TARGETING THE IMMUNOPHILIN FKBP12 BY DRUG REPURPOSING OR RNASE-BASED APPROACHES FOR BMP-SMAD PATHWAY AND HEPCIDIN UPREGULATION IN HEREDITARY HEMOCHROMATOSIS
EHA Learning Center, Mariateresa Pettinato, 267382
UPDATED RESULTS FROM THE HGB-206 STUDY IN PATIENTS WITH SEVERE SICKLE CELL DISEASE TREATED UNDER A REVISED PROTOCOL WITH LENTIGLOBIN GENE THERAPY USING PLERIXAFOR-MOBILISED HAEMATOPOIETIC STEM CELLS
EHA Learning Center, Julie Kanter, 267387
INTERRUPTING QUINOLONE PROPHYLAXIS IN HEMATOLOGIC PATIENTS WITH PROLONGED NEUTROPENIA: AN OBSERVATIONAL STUDY
EHA Learning Center, Alvaro Bienert García, 267392
INCIDENCE, RISK FACTORS AND OUTCOMES OF THROMBOEMBOLISM EVENTS IN HAPLOIDENTICAL VS. MATCHED RELATED DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION
EHA Learning Center, Gaochao zhang, 267397
PET-DRIVEN RADIOTHERAPY IN PATIENTS WITH LOW RISK DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) : THE DLCL10 MULTICENTER PHASE 2 TRIAL BY FONDAZIONE ITALIANA LINFOMI (FIL)
EHA Learning Center, Monica Balzarotti, 267351
CARFILZOMIB AND DEXAMETHASONE MAINTENANCE PROLONG TIME TO PROGRESSION FOLLOWING SALVAGE ASCT IN MULTIPLE MYELOMA: A RANDOMIZED PHASE 2 TRIAL BY THE NORDIC MYELOMA STUDY GROUP
EHA Learning Center, Henrik Gregersen, 267356
MOLECULAR ANALYSIS IN MAJIC PV CORRELATION WITH CLINICAL ENDPOINTS.
EHA Learning Center, Natalia Curto-Garcia, 267361
MOLECULAR MRD STATUS AND OUTCOME AFTER TRANSPLANTATION IN NPM1 MUTATED AML: RESULTS FROM THE UK NCRI AML17 STUDY
EHA Learning Center, Richard DILLON, 267366
A DASATINIB-BLINATUMOMAB COMBINATION FOR THE FRONT-LINE TREATMENT OF ADULT PH+ ALL PATIENTS. PRELIMINARY RESULTS OF THE GIMEMA LAL2116 D-ALBA TRIAL; ON BEHALF OF GIMEMA ACUTE LEUKEMIA WORKING PARTY
EHA Learning Center, Sabina Chiaretti, 267371
TANDEM AUTOLOGOUS-REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANTATION IN HIGH-RISK RELAPSED HODGKIN LYMPHOMA: A RETROSPECTIVE STUDY OF THE LWP-EBMT
EHA Learning Center, Leyre Bento de Miguel, 267376
THE HEMOCHROMATOSIS PROTEINS HJV AND TFR2 ARE DISPENSABLE FOR ACUTE BMP2-MEDIATED HEPCIDIN UPREGULATION IN MICE
EHA Learning Center, Alessia Pagani, 267381
SAFETY AND EFFICACY OF LENTIGLOBIN GENE THERAPY IN PATIENTS WITH TRANSFUSION-DEPENDENT B-THALASSAEMIA AND NON-B0/B0 GENOTYPES IN THE PHASE 3 NORTHSTAR-2 STUDY
EHA Learning Center, Franco Locatelli, 267386
A BAL-DRIVEN ANTIMICROBIAL TREATMENT IMPROVES CLINICAL OUTCOME IN HEMATOLOGIC MALIGNANCIES PATIENTS WITH LUNG INFILTRATES DETECTION: A PROSPECTIVE MULTICENTER STUDY OF THE SEIFEM GROUP
EHA Learning Center, Francesco MARCHESI, 267391
DEVELOPMENT OF A CLINICAL PREDICTION RULE FOR VENOUS THROMBOEMBOLISM IN PATIENTS WITH ACUTE LEUKEMIA
EHA Learning Center, Alejandro Lazo-Langner, 267396
IS QUERCETIN ABLE TO REVERT THE APOPTOTIC RESISTANCE TRIGGERED BY THE SHORT ISOFORM OF GATA-1 IN MYELOID LEUKEMIA CELLS?
EHA Learning Center, Silvia trombetti, 266630
CLINICAL BENEFIT OF GLASDEGIB PLUS LOW-DOSE CYTARABINE IN PATIENTS WITH DE NOVO AND SECONDARY ACUTE MYELOID LEUKEMIA: LONG-TERM ANALYSIS OF A PHASE 2 RANDOMIZED TRIAL
EHA Learning Center, Michael Heuser, 266646
INDIRECT NUMBER NEEDED TO TREAT: COMPARATIVE EFFECTIVENESS OF GLASDEGIB + LOW-DOSE CYTARABINE VS AZACITIDINE OR DECITABINE IN ACUTE MYELOID LEUKEMIA PATIENTS INELIGIBLE FOR INTENSIVE CHEMOTHERAPY
EHA Learning Center, Gabriel Tremblay, 266662
ELDERLY PATIENTS WITH DE NOVO OR SECONDARY AML HAVE COMPARABLE OUTCOMES AFTER INTENSIVE TREATMENTS INCLUDING HIGH DOSE (HD) CYTARABINE AND AUTOLOGOUS (AUTO) OR ALLOGENEIC (ALLO) TRANSPLANTATION (SCT)
EHA Learning Center, Massimo Bernardi, 266678
PEDIATRIC ACUTE MYELOID LEUKEMIA (AML) IN DEVELOPING COUNTRIES, BARRIERS AGAINST BETTER OUTCOME 10 YEARS’ EXPERIENCE AMONG EGYPTIAN PEDIATRIC ACUTE MYELOID LEUKEMIA
EHA Learning Center, Youssef Madney, 266679
A PHASE II STUDY OF FRACTIONATED CYCLOPHOSPHAMIDE, VINBLASTINE, ORAL ETOPOSIDE AND PREDNISOLONE IN PATIENTS WITH ACQUIRED IMMUNODEFICIENCY SYNDROME RELATED LYMPHOMAS
EHA Learning Center, Hasmukh Jain, 266695
CLINICAL OUTCOME OF INTENSIFIED CHEMO-TARGETED THERAPY IN ACTIVATED B CELL NON HODGKIN LYMPHOMA
EHA Learning Center, Ahmed Sohaib, 266696
MANAGING CYTOKINE RELEASE SYNDROME (CRS) AND NEUROTOXICITY WITH STEP-FRACTIONATED DOSING OF MOSUNETUZUMAB IN RELAPSED/REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (NHL)
EHA Learning Center, Sung-Soo Yoon, 266711
RAPID INFUSION WITH CT-P10 IN PATIENTS WITH NON-HODGKIN’S LYMPHOMA OR CHRONIC LYMPHOCYTIC LEUKAEMIA: INTERIM RESULTS FROM A EUROPEAN NON-INTERVENTIONAL POST-AUTHORISATION SAFETY STUDY
EHA Learning Center, Mark J Bishton, 266712
OLIGOCLONALITY OF T-CELL RECEPTOR AND THE MAIN SUBPOPULATION COMPOSITION IN PATIENTS WITH APLASTIC ANEMIA AT DIFFERENT STAGES OF THE DISEASE.
EHA Learning Center, Anastasia Abramova, 266730
PATIENTS WITH GAUCHER DISEASE SHOW AN IMMUNE-DYSREGULATION PATTERN SECONDARY TO A DEFECT OF APOPTOSIS
EHA Learning Center, Maurizio Miano, 266731
CLL- DERIVED EXOSOMES REPROGRAM RESIDENT CELLS TO BECOME CLL SUPPORTIVE CELLS
EHA Learning Center, Orit Uziel, 266746
STEM CELL FACTOR IS IMPLICATED IN MICROENVIRONMENTAL INTERACTIONS AND CELLULAR DYNAMICS OF CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Learning Center, George Gavriilidis, 266747
TARGETED ACTIVATION OF THE PROTEIN PHOSPHATASES SHP-1 AND PP2A ABROGATES CONSTITUTIVE ACTIVATION OF SURVIVAL PATHWAYS IN LARGE GRANULAR LYMPHOCYTE LEUKEMIA (LGLL)
EHA Learning Center, Mario Pagano, 266762
LOW-COVERAGE WHOLE GENOME SEQUENCING OUTPERFORMS FISH IN COPY NUMBER VARIATION DETECTION IN CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Learning Center, Beñat Ariceta, 266763
EFFICACY AND SAFETY OF IBRUTINIB IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS PREVIOUSLY TREATED WITH VENETOCLAX IN THE MURANO STUDY
EHA Learning Center, Richard Greil, 266778
COMBINATION THERAPY TO PREVENT IBRUTINIB WITHDRAWAL: CONTINUED IBRUTINIB WITH THE ADDITION OF VENETOCLAX AT TIME OF PROGRESSION IN IBRUTINIB-TREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
EHA Learning Center, Paul Hampel, 266779
PROGNOSTIC FACTORS FOR MOLECULAR RELAPSE-FREE SURVIVAL AFTER DISCONTINUATION OF TYROSINE KINASE INHIBITORS IN CHRONIC MYELOID LEUKEMIA BASED ON RUSSIAN MULTICENTER PROSPECTIVE TRIAL (RU-SKI)
EHA Learning Center, Oleg Shukhov, 266794
TREATMENT AND OUTCOME OF CHRONIC MYELOID LEUKEMIA IN CHILDREN AND ADOLESCENTS: THE INDIAN PEDIATRIC ONCOLOGY GROUP-CML-16-01 MULTICENTRIC STUDY
EHA Learning Center, Sidharth Totadri, 266795
CHARACTERISTICS AND OUTCOMES OF THE TREATMENT PATIENTS WITH T315I MUTATION CML
EHA Learning Center, Julia Vlasova, 266810
NKG2D AND BCMA-CAR NK CELLS EFFICIENTLY ELIMINATE MULTIPLE MYELOMA CELLS. A COMPREHENSIVE COMPARISON BETWEEN TWO CLINICALLY RELEVANT CARS.
EHA Learning Center, Elena Maroto-Martín, 266826
NOVEL PRO-INFLAMMATORY MACROPHAGES ARE INVOLVED IN HEMATOPOIETIC STEM CELL DEVELOPMENT
EHA Learning Center, Elaine Dzierzak, 266842
JAK-INHIBITION WITH RUXOLITINIB IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA: A PHASE II, OPEN LABEL, MULTICENTER CLINICAL TRIAL (JERICHO)
EHA Learning Center, Bastian von Tresckow, 266860
LONG-TERM FOLLOW-UP OF JCOG0406 STUDY: INTENSIVE IMMUNOCHEMOTHERAPY (R-HIGH CHOP/CHASER) FOLLOWED BY HIGH-DOSE CHEMOTHERAPY (LEED) WITH AUTO-PBSCT IN UNTREATED MANTLE CELL LYMPHOMA
EHA Learning Center, Michinori Ogura, 266876
INVASIVE ASPERGILLOSIS CAUSED BY 'RARE' PATHOGENS: CLINICAL REGISTRY DATA ANALYSIS
EHA Learning Center, Nikolay Klimko, 266892
THE DEVELOPMENT OF IRON OVERLOAD SYNDROME IN PATIENTS WITH LOW-/INTERMEDIATE RISK MYELODYSPLASTIC SYNDROME
EHA Learning Center, Tatiana Babaeva, 266908
USE OF T CELL-SPECIFIC RNA IN SITU HYBRIDISATION AS A NOVEL TEST TO DISTINGUISH MALIGNANT (LYMPHOMATOUS) AND BENIGN (INFLAMMATORY) T CELL INFILTRATES
EHA Learning Center, Elizabeth Soilleux, 266924
HIGH SERUM LEVELS OF IL-2R, IL-6 AND TNF ARE ASSOCIATED WITH HIGHER TUMOR BURDEN AND POORER OUTCOME IN PATIENTS WITH NEWLY DIAGNOSED FOLLICULAR LYMPHOMA
EHA Learning Center, Pablo Mozas, 266940
UNSUPERVISED HIERARCHICAL CLUSTERING OF PRE-TREATMENT IMMUNOPHENOTYPIC FEATURES IDENTIFIES MDS PATIENTS AT HIGH RISK OF DISEASE PROGRESSION AFTER ALLOGENEIC TRANSPLANTATION
EHA Learning Center, Jentzsch Madlen, 266956
INDIRUBIN-3’-MONOXIME INDUCES APOPTOSIS AND OVERCOMES BORTEZOMIB RESISTANCE IN MULTIPLE MYELOMA VIA TARGETING THE UBIQUITIN AND PROTEASOME SYSTEM
EHA Learning Center, Zhen yu, 266973
B-CELL MATURATION ANTIGEN ANTIBODY-DRUG CONJUGATE (ADC), GSK2857916, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): FINAL SAFETY, EFFICACY AND PHARMACOKINETIC (PK) ANALYSES FROM A PHASE I STUDY
EHA Learning Center, Rakesh Popat, 266989
RELATIVE EFFICACY OF APPROVED AND RECENTLY INTRODUCED TREATMENTS FOR NEWLY DIAGNOSED MULTIPLE MYELOMA: A NETWORK META-ANALYSIS
EHA Learning Center, Katja C Weisel, 267005
RELATIONSHIP BETWEEN COMORBIDITY AND ELIGIBILITY CRITERIA FOR CLINICAL TRIALS IN MULTIPLE MYELOMA. A CRITICAL APPRAISAL.
EHA Learning Center, Ernesto Pérez Persona, 267021
RESULTS FROM A POST-AUTHORIZATION SAFETY STUDY COMPARING LENALIDOMIDE-BASED WITH NON-LENALIDOMIDE-BASED TREATMENT IN TRANSPLANT-INELIGIBILE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
EHA Learning Center, Valerio De Stefano, 267037
IFN-Α TREATMENT NORMALIZES THE PLATELET COUNTS AND REDUCES QUIESCENT STEM CELLS IN A CALR-DEL52 TRANSGENIC MOUSE MODEL, IN VIVO.
EHA Learning Center, Harini Nivarthi, 267053
CURCUMIN INHIBITS PROLIFERATION AND INDUCES APOPTOSIS IN JAK2 MUTATED CELLS THROUGH THE INHIBITION OF JAK2/STAT AND MTORC1 PATHWAYS
EHA Learning Center, Jessica Petiti, 267070
IL28B GENE POLYMORPHISMS INFLUENCE ON THE RESPONSIVENESS AND TOLERABILITY OF IFN-Α IN PATIENTS WITH MPN
EHA Learning Center, Marina Stolyar, 267086
INTERLEUKIN-33 IN PEDIATRIC PATIENTS WITH IMMUNE THROMBOCYTOPENIA: RELATION TO PROGNOSIS AND TREATMENT OUTCOME
EHA Learning Center, Azza Tantawy, 267103
VALIDATION OF HAND GRIP STRENGTH AS A SCREENING TOOL FOR FRAILTY IN OLDER PATIENTS ON TREATMENT FOR HEMATOLOGIC MALIGNANCIES: THE FRAILTY TASK FORCE STUDY
EHA Learning Center, Tommasina GUGLIELMELLI, 267119
GENOME EDITING OF HBG1/2 PROMOTER LEADS TO ROBUST HBF INDUCTION IN VIVO, WHILE EDITING OF BCL11A ERYTHROID ENHANCER RESULTS IN ERYTHROID DEFECTS
EHA Learning Center, Kaihsin Chang, 267135
EFFICACY AND SAFETY OF STEM CELL MOBILISATION FOLLOWING GDP SALVAGE IN PATIENTS WITH RELAPSED OR REFRACTORY LYMPHOMA
EHA Learning Center, Catherine Tang, 267151
INTENSIVE ORAL CARE CAN REDUCE BLOOD STREAM INFECTION POST NEUTROPHIL ENGRAFTMENT IN ALLOGENEIC HSCT
EHA Learning Center, Tatsuya Suwabe, 267168
MAGIC-TT (MAGNETISM-INDUCED CELL TARGET TRANSPLANTATION) IMPROVES THE EFFECT OF INTRA-BONE MARROW TRANSPLANTATION: FASTER HEMATOPOIETIC RECONSTITUTION AND BETTER SURVIVAL IN MURINE MODEL
EHA Learning Center, Qiusui mai, 267185
A PHASE II DOSE-FINDING STUDY OF DALTEPARIN IN CHILDREN WITH VTE WITH OR WITHOUT CANCER
EHA Learning Center, Nancy Sherman, 267201
TCF7-SPI1 AND NRAS (G12D) COOPERATE IN THE DEVELOPMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Quentin Van Thillo, 267217
HIV INTEGRASE INHIBITOR MK-2048 INDUCES APOPTOSIS IN HTLV-1 INFECTED CELLS THROUGH THE UPR ACTIVATION.
EHA Learning Center, Emi Ikebe, 267233
INOTUZUMAB OZOGAMICIN (INO) TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA (R/R ALL): OUTCOMES OF PATIENTS TREATED IN SALVAGE ONE WITH A LONG DURATION OF FIRST REMISSION
EHA Learning Center, Matthias Stelljes, 267250
A NOVEL FAST CD19 CAR-T CELLS: RAPID AND EFFICIENT TREATMENT FOR REFRACTORY B-ALL(BP-CML)
EHA Learning Center, Xi Zhang, 267266
THE ROLE OF STAT3 ISOFORMS IN ACUTE MYELOID LEUKEMIA
EHA Learning Center, Dagmar Stoiber, 267283
SINGLE CELL SIGNALING PHARMACODYNAMICS IN A PHASE 1B CLINICAL TRIAL OF THE AXL INHIBITOR BEMCENTINIB IN ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME
EHA Learning Center, Oda Helen Eck, 267300

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings